Alzheimer's biotech comes un­der at­tack as pe­ti­tion calls for tri­al halt, da­ta au­dit — and it's fight­ing back

Lit­tle Cas­sa­va Sci­ences has com­plete faith in its ex­per­i­men­tal Alzheimer’s drug. Ever since piv­ot­ing away from a four-time re­ject anal­gesic (and from its for­mer iden­ti­ty …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER